Alzheimer's disease: Pharmacological treatment and management

Clinical Neuropsychologist

Volumn 14, Issue 1, 2000, Pages 93-109

  Rivas Vazquez, Rafael A ^a,b,d   Carrazana, Enrique J ^a,b   Rey, Gustavo J ^a,b   Blais, Mark A ^c   Racher, David A ^a  

^a Neurologic Center of South Florida   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; AMITRIPTYLINE; AMYLOID BETA PROTEIN; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BETA SECRETASE; BUSPIRONE; CARBAMAZEPINE; CHLORPROMAZINE; CHOLINESTERASE INHIBITOR; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; DESIPRAMINE; DONEPEZIL; DOPAMINE RECEPTOR; FLUOXETINE; FLUVOXAMINE MALEATE; FREE RADICAL; GALANTAMINE; HALOPERIDOL; HUPERZINE A; LORAZEPAM; METRIFONATE; MILAMELINE; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; OXAZEPAM; PAROXETINE; PHYSOSTIGMINE; QUETIAPINE; RISPERIDAL; RISPERIDONE; RIVASTIGMINE; SEROTONIN; SERTINDOLE; SERTRALINE; TACRINE; TRAZODONE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VENLAFAXINE; XANOMELINE; ZIPRASIDONE; ZOLPIDEM TARTRATE;

ALZHEIMER DISEASE; ANXIETY NEUROSIS; ARTICLE; BEHAVIOR DISORDER; BEHAVIOR MODIFICATION; BRAIN CORTEX ATROPHY; CHOLINERGIC TRANSMISSION; CLINICAL TRIAL; COGNITIVE DEFECT; DELUSION; DEPRESSION; DOSE RESPONSE; DRUG INHIBITION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SCREENING; ENZYME SPECIFICITY; GASTROINTESTINAL INFECTION; HEALTH CARE COST; HUMAN; LIVER TOXICITY; MUSCLE CRAMP; PREVALENCE; PSYCHOSIS; TREATMENT OUTCOME; XEROSTOMIA;

EID: 0033887141     PISSN: 13854046     EISSN: None     Source Type: Journal    
DOI: 10.1076/1385-4046(200002)14:1;1-8;FT093     Document Type: Article

References (141)

1. Aisen, P.S., & Davis, K.L. (1997). Anti-inflammatory therapy for Alzheimer's disease: A status report. International Journal of Geriatric Psychopharmacology, 1, 2-5.
2. Aisen, P.S., Davis, K.L., Berg, J.D., Schafer, K., Campbell, K., Thomas, R.G., Weiner, M.F., Farlow, M.R., Sano, M., Grundman, M., & Thal, L.J. (2000). A randomized controlled trial of prednisone in Alzheimer's disease. Neurology, 54, 588-593.
3. Albert, M.S., & Moss, M.B. (1992). The assessment of memory disorders in patients with Alzheimer's disease. In L.R. Squire & N. Butters (Eds.), Neuropsychology of memory (pp. 211-219). New York: The Guilford Press.
4. Alexopoulos, G.S., Silver, J.M., Kahn, D.A., Frances, A., & Carpenter, D. (1998). The expert consensus guidelines series: Treatment of agitation in older persons with dementia. Postgraduate Medicine, 3, 1-88.
5. American Psychiatric Association (1997). Practice guidelines for the treatment of patients with Alzheimer's disease and other dementias of late life. American Journal of Psychiatry, 154, 1-39.
6. Arvanitis, L.A., & Rak, I.W. (1997). Efficacy, safety, and tolerability of "Seroquel" (quetiapine) in elderly patients with psychotic disorders. Schizophrenia Research, 24, 196.
7. Becker, R.E., Colliver, J.A., Markwell, S.J., Moriearty, P.L., Unni, L.K., & Vicari, S. (1998). Effects of metrifonate on cognitive decline in Alzheimer's disease: A double-blind, placebo-controlled 6-month study. Alzheimer's Disease and Associated Disorders, 12, 54-57.
8. Bender, K.J. (1998). Treating behavioral and cognitive symptoms of Alzheimer's disease. Psychiatric Times, 15, 1-4.
9. Birge, S.J. (1997). The role of estrogen in the treatment of Alzheimer's disease. Neurology, 48, S36-S41.
10. Bleich, A., Brown, S.L., Kahn, R., & Van Praag, H.M. (1988). The role of serotonin in schizophrenia. Schizophrenia Bulletin, 14, 297-315.
11. Bodick, N., Offen, W., Shannon, H.E., Satterwhite, J., Lucas, R., van Lier, R., & Paul, S.M. (1997). The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer's disease. Alzheimer Disease and Associated Disorders, 11, 16-22.
12. Bondareff, W., Mountjoy, C.Q., & Roth, M. (1982). Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus ceruleus) in senile dementia. Neurology, 32, 164-168.
13. Buchanan, R.W., Holstein, C., & Breier, A. (1994). The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biological Psychiatry, 36, 717-725.
14. Casey, D.E. (1998). Effects of clozapine therapy in schizophrenic individuals at risk for tardive dyskinesia. Journal of Clinical Psychiatry, 59, 31-37.
15. Civil, R.H., Whitehouse, P.J., Lanska, D.J., & Mayeux, R. (1993). Degenerative dementias. In P.J. Whitehouse (Ed.), Dementia (pp. 167-236). Philadelphia: F.A. Davis Company.
16. Coccaro, E.F., Siever, L.J., & Klar, H.M. (1989). Serotonergic studies in patients with affective and personality disorders: Correlates with suicidal and impulsive aggressive behaviors. Archives of General Psychiatry, 46, 587-599.
17. Cohen, G., & Spina, M.B. (1989). Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Annals of Neurology, 26, 689-690.
18. Corey-Bloom, J., Anand, R., & Veach, J. (1998). A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetlycholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. International Journal of Geriatric Psychopharmacology, 1, 55-65.
19. Crimson, M.L. (1998). Pharmacokinetics and drug interactions of cholinesterase inhibitors administered in Alzheimer's disease. Pharmacotherapy, 18, 47-54.
20. Cummings, J.L. (2000). Cholinesterase inhibitors: A new class of psychotropic compounds. American Journal of Psychiatry, 157, 4-15.
21. Cummings, J.L. (1998a). Alzheimer's disease management. Journal of Clinical Psychiatry, 59, 4-5.
22. Cummings, J.L. (1998b). Metrifonate: Overview of safety and efficacy. Pharmacotherapy, 18, 43-46.
23. Cummings, J.L. (1998c). New developments in the treatment of Alzheimer's disease. Psychiatric Times, 15, 50-54.
24. Cummings, J.L., Cyrus, P.A., Bieber, F., Mas, J., Orazem, J., & Gulanski, B. (1998). Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Neurology, 50, 1214-1221.
25. Cummings, J.L., & Kaufer, D.I. (1996). Neuropsychiatric aspects of Alzheimer's disease: The cholinergic hypothesis revisited. Neurology, 47, 876-883.
26. Cummings, J.L., & Masterman, D.L. (1998). Assessment and treatment-associated changes in behavior and cholinergic therapy of neuropsychiatric symptoms in Alzheimer's disease. Journal of Clinical Psychiatry, 59, 23-30.
27. Daniel, D.G., & Whitcomb, S.R. (1998). Treatment of the refractory schizophrenic patient. Journal of Clinical Psychiatry, 59, 13-19.
28. Davis, K.L. (1998). Future therapeutic approaches to Alzheimer's disease. Journal of Clinical Psychiatry, 59, 14-16.
29. De Deyn, P.P., Rabheru, K., Rasmussen, A., Bocksberger, J.P., Dautzenberg, P.L.J., Eriksson, S., & Lawlor, B.A. (1999). A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology, 53, 946-955.
30. Deutsch, L.H., Bylsma, F.W., Rovner, B.W., Steele, C., & Folstein, M.F. (1991). Psychosis and physical aggression in probable Alzheimer's disease. American Journal of Psychiatry, 148, 1159-1163.
31. Ernst, R., & Hay, J. (1994). The U.S. economic and social costs of Alzheimer's disease revisited. American Journal of Public Health, 84, 1261-1264.
32. Evans, D.A., Funkenstein, H.H., Albert, M.S., Scherr, P.A., Cook, N.R., Chown, M.J., Hebert, L.E., Hennekens, C.H., & Taylor, J.O. (1989). Prevalence of Alzheimer' s disease in a community population of older persons: Higher than previously reported. Journal of the American Medical Association, 262, 2551-2556.
33. Exelon approved for European market (1998). Psychiatric Times, 15 (8), 35.
34. Farlow, M., Gracon, S.I., Hershey, L.A., Lewis, K.W., Sadowsky, C.H., & Dolan-Ureno, J. (1992). A controlled trial of tacrine in Alzheimer's disease. Journal of the American Medical Association, 268, 2523-2529.
35. Felician, O., & Sandson, T.A. (1999). The neurobiology and pharmacotherapy of Alzheimer's disease. The Journal of Neuropsychiatry and Clinical Neurosciences, 11, 19-31.
36. Fillit, H., Weinreb, H., & Choisi, I. (1986). Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type. Psychoneuroendocrinology, 11, 337-345.
37. Fogel, B.S. (1996). Drug therapy in neuropsychiatry. In B.S. Fogel & R.B. Schiffer (Eds.), Neuropsychiatry (pp. 223-256). Baltimore, MD: Williams & Wilkins.
38. Geldmacher, D.S., Lerner, A.J., Voci, J.M., Noelker, E.A., Somple, L.C., & Whitehouse, P.J. (1997). Treatment of functional decline in adults with Down syndrome using selective serotonin-reuptake inhibitor drugs. Journal of Geriatric Psychiatry and Neurology, 10, 99-104.
39. Goldberg, T.E., & Weinberger, D.R. (1994). The effects of clozapine on neurocognition: An overview. Journal of Clinical Psychiatry, 55, 88-90.
40. Goodman, Y., & Mattson, M.P. (1994). Secreted forms of beta amyloid precursor protein protect hippocampal neurons against anyloid beta peptide induced oxidative injury. Experimental Neurology, 128, 1-12.
41. Gottfries, C.G., Karlsson, I., & Nyth, A.L. (1992). Treatment of depression in elderly patients with and without dementia disorders. International Journal of Clinical Psychopharmacology, 6, 55-64.
42. Green, M.F., Marshall, B.D., Wirshing, W.C., Ames, D., Marder, S.R., McGurk, S., Kern, R.S., & Mintz, J. (1997). Does risperidone improve verbal working memory in treatment-resistant schizophrenia. American Journal of Psychiatry, 154, 799-804.
43. Harvey, P.D., & Keefe, R.S. (1997). Cognitive impairment in schizophrenia and implications of atypical neuroleptic treatment. CNS Spectrums, 2, 41-55.
44. Henderson, V.W., Paganini, A., Miller, B.L., Elble, R.J., Reyes, P.F., Shoupe, D., McCleary., C.A., Klein, R.A., Hake, A.M., & Farlow, M.R. (2000). Estrogen for Alzheimer's disease in women. Neurology, 54, 295-301.
45. Herrmann, N. (1998). Valproic acid treatment of agitation in dementia. Canadian Journal of Psychiatry, 43, 69-72.
46. Horne, M., & Lindley, S.E. (1995). Divalproex sodium in the treatment of aggressive behavior and dysphoria in patients with organic brain syndromes. Journal of Clinical Psychiatry, 56, 430-431.
47. Jacobs, D.M., Tang, M.X., Stern, Y., Sano, M., Marder, K., Bell, K.L., Schofield, P., Dooneief, G., Gurland, B., & Mayeux, R. (1998). Cognitive function in nondemented older women who took estrogen after menopause. Neuorology, 50, 368-373.
48. Jann, M.W. (1998). Preclinical pharmacology of metrifonate. Pharmacotherapy, 18, 56-67.
49. Jay, G. (1997). Alzheimer's disease: From gene to pathology. American Journal of Psychiatry, 154, 1359.
50. Jeste, D.V., Caligiuri, M.P., Paulsen, J.S., Heaton, R.K., Lacro, J.P., Harris, M.J., Bailey, A., Fell, R.L., & McAdams, L.A. (1995). Risk of tardive dyskinesia in older patients: A prospective longitudinal study of 266 outpatients. Archives of General Psychiatry, 52, 756-765.
51. Jeste, D.V., Klauser, M., Brecher, M., Clyde, C., & Jones, R. (1997). A clinical evaluation of risperdone in the treatment of schizophrenia: A 10-week, open-label, multicenter trial. Psychopharmacology, 131, 239-247.
52. Jones, H., Curtis, V.A., Wright, P., & Lucey, J.V. (1998). Neuroendocrine evidence that clozapine's serotonergic antagonism is relevant to its efficacy in treating hallucinations and other positive schizophrenic symptoms. American Journal of Psychiatry, 155, 838-840.
53. Kapur, S., & Remington, G. (1996). Serotonin-dopamine interaction and its relevance to schizophrenia. American Journal of Psychiatry, 153, 466-476.
54. Karlsson, I. (1996). Treatment of non-cognitive symptoms in dementia. Acta Neurologica Scandinavia, 168, 93-95.
55. Kaufer, D.I., Cummings, J.L., & Christine, D. (1996). Effect of tacrine on behavioral symptoms in Alzheimer's disease: An open-label study. Journal of Geriatric Psychiatry and Neurology, 9, 1-6.
56. Katz, I.R. (1998). Diagnosis and treatment of depres-sion in patients with Alzheimer's disease and other dementias. Journal of Clinical Psychiatry, 59, 38-44.
57. Katz, I.R., Jeste, D.V., & Mintzer, J.E. (1999). Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial. Journal of Clinical Psychiatry, 60, 107-115.
58. Khachaturian, Z.S. (1998). Introduction to pharmacologic advances in Alzheimer's disease. Pharmacotherapy, 18, 31-32.
59. Knapp, M.J., Knopman, D.S., Solomon, P.R., Pendlebury, W.W., Davis, C.S., & Gracon, S.I. (1994). A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. Journal of the American Medical Association, 271, 985-991.
60. Knopman, D.S., Schneider, L., Davis, K., Talwalker, S., Smith, F., Hoover, T., & Gracon, S. (1997). Long-term tacrine (Cognex) treatment: Effects on nursing home placement and mortality. Neurology, 47, 166-177.
61. Kumar, V. (1997). Use of antipsychotic agents in geriatric patients: A review. International Journal of Geriatric Psychopharmacology, 13, 15-23.
62. Kunik, M.E., Puryear, L., & Orengo, C.A. (1998). The efficacy and tolerability of divalproex sodium in elderly demented patients with behavioral disturbances. International Journal of Geriatric Psychiatry, 13, 29-34.
63. LeBars, P.L., Katz, M.M., Berman, N., Itil, T.M., Freedman, A.M., & Schatzberg, A.F. (1997). A placebo-controlled, double-blind, randomized trial of an extract of ginkgo biloba for dementia. Journal of the American Medical Association, 278, 1327-1332.
64. Lee, M., Thompson, P., & Meltzer, H.Y. (1994). Effects of clozapine on cognitive function in schizophrenia. Journal of Clinical Psychiatry, 55, 82-87.
65. Lott, A.D., McElroy, S.L., & Keys, M.A. (1995). Valproate in the treatment of behavioral agitation in elderly patients with dementia. Journal of Neuropsychiatry and Clinical Neuroscience, 7, 314-319.
66. Mackle, M., & Gottfries, C.G. (1998, May). Citalopram treatment of noncognitive symptoms in elderly demented patients. Paper presented at the 151st annual meeting of the American Psychiatric Association, Toronto, Canada.
67. Maixner, S.M., Mellow, A.M., & Tandon, R. (1999). The efficacy, safety and tolerability of antipsychotics in the elderly. Journal of Clinical Psychiatry, 60, 29-41.
68. Marder, S.R., & Van Putten, T. (1995). Antipsychotic medications. In A.F. Schatzberg & C. Nemeroff (Eds.), Textbook of Psychopharmacology (pp. 247-261). Washington, DC: American Psychiatric Press.
69. McGeer, E.G., & McGeer, P.L. (1998). Inflammation and Alzheimer's disease. Alzheimer's Disease Management Today, 1, 8-22.
70. McGurk, S.R. (1999). The effects of clozapine on cognitive functioning in schizophrenia. Journal of Clinical Psychiatry, 60, 24-29.
71. McGurk, S.R., Green, M.F., Wirshing, W.C., Ames, D., Marshall, B.D., Marder, S.R., & Mintz, J. (1997). The effects of risperidone versus haloperidol on cognitive functioning in treatment-resistant schizophrenia: The Trail Making Test. CNS Spectrums, 2, 60-64.
72. McMannus, D.Q., Arvantis, L.A., & Kowlacyk, B.B. (1999). Quetiapine, a novel antipsychotic: Experience in elderly patients with psychotic disorders. Journal of Clinical Psychiatry, 60, 292-298.
73. Meek, P.D., McKeithan, E.K., & Schumock, G.T. (1998). Economic considerations in Alzheimer's disease. Pharmacotherapy, 18, 68-73.
74. Mega, M.S., Cummings, J.L., Fiorello, T., & Gornbein, J. (1996). The spectrum of behavioral changes in Alzheimer's disease. Neurology, 46, 130-135.
75. Meltzer, H.Y. (1992). Dimensions of outcome with clozapine. British Journal of Psychiatry, 160, 46-53.
76. Middlemiss, P.J., Glasky, A.J., Rathbone, M.P., Werstuik, E., Hindley, S., & Gysbers, J. (1995). AIT-082, a unique purine derivative, enhances nerve growth factor mediated neurite outgrowth from PC-12 cells. Neuroscience Letter, 199, 131-134.
77. Morris, J.C., Cyrus, P.A., Orazem, J., Mas, J., Bieber, F., Ruzicka, B.B., & Gulanski, B. (1998). Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology, 50, 1222-1230.
78. Narayan, M., & Nelson, J.C. (1997). Treatment of dementia with behavioral disturbance using divalproex or a combination of divalproex and a neuroleptic. Journal of Clinical Psychiatry, 58, 351-354.
79. Nyth, A.L., & Gottfries, C.G. (1990). The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders: A Nordic multicenter study. British Journal of Psychiatry, 157, 894-901.
80. Olafsson, K., Jorgenson, S., Jensen, H.V., Bille, A., Arup, P., & Andersen, J. (1992). Fluvoxamine in the treatment of demented elderly patients: A double-blind, placebo-controlled study. Acta Psychiatrica Scandinavia, 85, 435-436.
81. Passeri, M., Cucinotta, D., & De Mello, M. (1987). Comparison of minaprine and placebo in the treatment of Alzheimer's disease and multi-infarct dementia. International Journal of Geriatric Psychiatry, 2, 97-103.
82. Peskind, E.R. (1998). Pharmacologic approaches to cognitive deficits in Alzheimer's disease. Journal of Clinical Psychiatry, 59, 22-27.
83. Peskind, E.R., Wingerson, D., & Murray, S. (1995). Effects of Alzheimer's disease and normal aging on cerebrospinal fluid norepinephrine responses to yohimbine and clonidine. Archives of General Psychiatry, 52, 774-782.
84. Petracca, G., Teson, A., Chemerinski, E., Leiguarda, R., & Starkstein, S.E. (1996). A double-blind, placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease. Journal of Neuropsychiatry & Clinical Neurosciences, 8, 270-275.
85. Pies, R. (1998). Progress in psychoses: Safety and efficacy of atypical antipsychotics in schizophrenic and demented patients. Psychiatric Times, 15, 28-30.
86. Pollock, B.G., Mulsant, B.H., Sweet, R., Burgio, L.D., Kirshner, M.A., Shuster, K., & Rosen, J. (1997). An open pilot study of citalopram for behavioral disturbances of dementia: Plasma levels and real-time observations. American Journal of Geriatric Psychiatry, 5, 70-78.
87. Rabins, P.V. (1998). Developing treatment guidelines for Alzheimer's disease and other dementias. Journal of Clinical Psychiatry, 59, 17-19.
88. Raskind, M.A. (1998a). The clinical interface of depression and dementia. Journal of Clinical Psychiatry, 59, 9-12.
89. Raskind, M.A. (1998b). Psychopharmacology of noncognitive abnormal behaviors in Alzheimer's disease. Journal of Clinical Psychiatry, 59, 28-32.
90. Raskind, M.A. (1999). Evaluation and management of aggressive behavior in the elderly demented patient. Journal of Clinical Psychiatry, 60, 45-49.
91. Raskind, M.A., Cyrus, P.A., Ruzicka, B.B., & Gulanski, B.I. (1999). The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Journal of Clinical Psychiatry, 60, 318-325.
92. Raskind, M.A., Sadowsky, C.H., Sigmund, W.R., Beitler, P.J., & Auster, S.B. (1997). Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer's disease. Archives of Neurology, 54, 836-840.
93. Reynolds, F., Frank, E., & Kupfer, D. (1996). Treatment outcome in recurrent major depression: A post hoc comparison of elderly ("young old") and midlife patients. American Journal of Psychiatry, 153, 1288-1292.
94. Ringman, J.M., & Cummings, J.L. (1999). Metrifonate: Update on a new antidementia agent. Journal of Clinical Psychiatry, 60, 776-782.
95. Rivas-Vazquez, R., & Blais, M.A. (1997). Selective serotonin reuptake inhibitors and atypical antidepressants: A review and update for psychologists. Professional Psychology: Research and Practice, 28, 526-536.
96. Rogers, J., Kirby, L.C., Hempelman, S.R., Berry, D.L., McGeer, P.L., Kaszniak, A.W., Zalinski, J., Cofield, M., Mansukhani, L., & Willson, P. (1993). Clinical trial of indomethacin in Alzheimer's disease. Neurology, 43, 1609-1611.
97. Rogers, S.L., Farlow, M.R., Doody, R.S., Mohs, R., & Friedhoff, L.T. (1998). A 24-week double-blind, placebo-controlled trial of donepezil in patients with Alzheimer' s disease. Neurology, 50, 136-145.
98. Rogers, S.L., & Friedhoff, L.T. (1996). The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a U.S. multicenter, randomized, double-blind, placebo-controlled trial. Dementia, 7, 293-303.
99. Roose, S.P., & Suthers, K.M. (1998). Antidepressant response in late-life depression. Journal of Clinical Psychiatry, 59, 4-8.
100. Rosen, W.G., Mohs, R.C., & Davis, K.L. (1984). A new rating scale for Alzheimer's disease. American Journal of Psychiatry, 141, 1356-1364.
101. Roth, M., Mountjoy, C.O., & Amrein, R. (1996). Moclobemide in elderly patients with cognitive decline and depression: An international double-blind, placebo-controlled trial. British Journal of Psychiatry, 168, 149-157.
102. Rother, M., Erkinjuntti, T., Roessner, M., Marcusson, J., & Karlsonn, I. (1998). Propentofylline in the treatment of Alzheimer's disease and vascular dementia: A review of phase III trials. Dementia & Geriatric Cognitive Disorders, 9, 36-43.
103. Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H.B., Hartman, A., & Gharabawi, M. (1999). Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. British Medical Journal, 318, 633-640.
104. Safferman, A., Lieberman, J.A., Kane, J.M., Szymanski, S., & Kinon, B. (1991). Update on the clinical efficacy and side effects of clozapine. Schizophrenic Bulletin, 17, 247-261.
105. Sano M., Ernesto, C., Thomas, R.G., Klauber, M.R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C.W., Pfeiffer, E., Schneider, L.S., & Thal, L.J. (1997). A controlled trial of selegiline, a-tocopherol or both as treatment for Alzheimer's disease. New England Journal of Medicine, 336, 1216-1222.
106. Schneider, L.S. (1998). New therapeutic approaches to cognitive impairment. Journal of Clinical Psychiatry, 59, 8-13.
107. Schneider, L.S. (1999). Pharmacologic management of psychosis in dementia. Journal of Clinical Psychiatry, 60, 54-60.
108. Schneider, L.S., Pollock, V.E., & Lyness, S.A. (1990). A meta-analysis of controlled trials of neuroleptic treatment in dementia. Journal of American Geriatric Society, 38, 553-563.
109. Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., Kholodenko, D., Lee, M., Liao, Z., Lieberburg, I., Motter, R., Mutter, L., Soriano, F., Shopp, G., Vasquez, N., Vandevert, C., Walker, S., Wogulis, M., Yednock, T., Games, D., & Seubert, P. (1999). Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature, 400, 173-177.
110. Serper, M.R., & Chou, J.Y.C. (1997). Novel neuroleptics improve attentional functioning in schizophrenic patients: Ziprasidone and aripiprazole. CNS Spectrums, 2, 56-59.
111. Small, G.W. (1998). The pathogenesis of Alzheimer's disease. Journal of Clinical Psychiatry, 59, 7-14.
112. Stahl, S.M. (1997). Excitotoxicity and neuroprotection. Journal of Clinical Neuropsychiatry, 58, 247-248.
113. Street, J., Clark, W.S., & Mitan, S. (1998, April). Olanzapine in the treatment of psychiatric disturbances with Alzheimer's disease. Paper presented at the annual meeting of the American Academy of Neurology, Ontario, Canada.
114. Sultzer, D.L., Gray, K.F., Gunay, I. Berisford, M.A., & Mahler, M.E. (1997). A double-blind comparison of trazadone and haloperidol for treatment of agitation in patients with dementia. American Journal of Geriatric Psychiatry, 5, 60-69.
115. Swartz, J.R., Miller, B.L., Lesser, I.M., & Darby, A.L. (1997). Frontotemporal dementia: Treatment response to serotonin selective reuptake inhibitors. Journal of Clinical Psychiatry, 58, 212-216.
116. Tandon, R., Milner, K., & Jibson, M.D., 1999). Antipsychotics from theory to practice: Integrating clinical and basic data. Journal of Clinical Psychiatry, 60, 21-28.
117. Tang, M.X., Jacobs, D., Stern, Y., Marder, K., Schofield, P., Gurland, B., Andrews, H., & Mayeux, R. (1996). Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet, 348, 429-432.
118. Taragano, F.E., Lyketsos, C.G., Mangone, C.A., Allegri, R.F., & Comesana-Diaz, E. (1997). A double-blind, randomized, fixed-dose trial of fluoxetine versus amitriptyline in the treatment of major depression complicating Alzheimer's disease. Psychosomatics, 38, 246-252.
119. Tariot, P.N. (1996). Treatment strategies for agitation and psychosis in dementia. Journal of Clinical Psychiatry, 57, 21-29.
120. Tariot, P.N. (1998). Evaluating response to metrifonate. Journal of Clinical Psychiatry, 59, 33-37.
121. Tariot, P.N. (1999). Treatment of agitation in dementia. Journal of Clinical Psychiatry, 60, 11-20.
122. Tariot, P.N., & Blazina, L. (1993). In J. Morris (Ed.), Handbook of dementing illnesses (pp. 461-475). New York: Marcel Dekker.
123. Tariot, P.N., Erb, R., Podgorski, C.A., Cox, C., Patel, S., Jakimovich, L., & Irvine, C. (1998). Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. American Journal of Psychiatry, 155, 54-61.
124. Tariot, P.N., Schneider, L.S., & Katz, I.R. (1995). Anticonvulsant and other non-neuroleptic treatment of agitation in dementia. Journal of Geriatrics, Psychiatry and Neurology, 8, 500-512.
125. Teri, L., Logsdon, R.G., Uomoto, J., & McCurry, S.M. (1997). Behavioral treatment of depression in dementia patients: A controlled clinical trail. Journal of Gerontology, 52, 159-166.
126. Thal, L.J., Schwartz, G., Sano, M., Weiner, M., Knopman, D., Harrell, L., Bodenheimer, S., Rossor, M., Philpot, M., Schor, J., & Goldberg, A. (1996). A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Neurology, 47, 1389-1395.
127. Trappler, B., & Vinuela, L.M. (1997). Fluvoxamine for stereotypic behavior in patients with dementia. Annals of Pharmacotherapy, 31, 578-581.
128. Tran, P.V., Dellva, M.A., Tollefson, G.D., Beasley, C.M., Potvin, J.H., & Kiesler, G.M. (1997). Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. Journal of Clinical Psychiatry, 58, 205-211.
129. Tune, L.E., Steele, C., & Cooper, T. (1991). Neuroleptic drugs in the management of behavioral symptoms of Alzheimer's disease. Psychiatric Clinics of North America, 14, 353-373.
130. Vassar, R., Bennett, B.D., Babu-Khan, S., Kahn, S., Mendiaz, E.A., Denis, P., Teplow, D.B., Ross, S., Amarante, P., Loeloff, R., Luo, Y., Fisher, S., Fuller, J., Edenson, S., Lile, J., Jarosinski, M.A., Biere, A.L., Curran, E., Burgess, T., Louis, J., Collins, F., Treanor, J., Rogers, G., & Citron, M. (1999). Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science, 286, 235-741.
131. Victoroff, J., Zarow, C., Mack, W.J., Hsu, E., & Chui, H.C. (1996). Physical aggression is associated with preservation of substantia nigra pars compacta in Alzheimer's disease. Archives of Neurology, 53, 428-434.
132. Volicer, L. (1999). Effective management of Alzheimer's disease. CNS Special Edition, 9-14.
133. Volicer, L., & Crino, P.B. (1990). Involvement of free radicals in dementia of the Alzheimer-type: A hypothesis. Neurobiology of Aging, 11, 567-571.
134. Volicer, L., Rheaume, Y., & Cyr, D. (1994). Treatment of depression in advanced Alzheimer's disease using sertraline. Journal of Geriatric Psychiatry & Neurology, 7, 227-229.
135. Wells, C.E., & Whitehouse, P.J. (1996). Cortical dementia. In B.S. Fogel & R.B. Schiffer (Eds.), Neuropsychiatry (pp. 871-893). Baltimore, MD: Williams & Wilkins.
136. Whitehouse, P.J., Price, D.L., Clark, A.W., Coyle, J.T., & DeLong, M.R. (1981). Alzheimer's disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis. Annals of Neurology, 10, 122-126.
137. Wilcox, G., & Wilkinson, D. (1996). Galanthamine hydrobromide - interim results of a group comparative, placebo-controlled study of efficacy and safety in patients with a diagnosis of senile dementia of the Alzheimer's type. Neurobiology of Aging, 17, 144.
138. Wragg, R.E., & Jeste, D.Y. (1989). Overview of depression and psychosis in Alzheimer's disease. American Journal of Psychiatry, 146, 577-587.
139. Zayas, E., & Grossberg, G.T. (1998). The treatment of psychosis in late life. Journal of Clinical Psychiatry, 59, 5-10.
140. Zubenko, G.S., Moossy, J., & Kopp, U. (1990). Neurochemical correlates of major depression in primary dementia. Archives of Neurology, 45, 1182-1186.
141. Zweig, R.M., Ross, C.A., Hedreen, J.C., Steele, C., Cardillo, J.E., Whitehouse, P.J., Folstein, M.F., & Price, D.L. (1989). Neuropathology of aminergic nuclei in Alzheimer's disease. Progress in Clinical & Biological Research, 317, 353-365.